TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...
A partnership comprising TransCode Therapeutics and Quantum Leap Healthcare Collaborative has submitted an investigational ...
TransCode is the only company with an ongoing US clinical trial targeting microRNA in cancer BOSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology ...
Shares of TransCode Therapeutics, Inc.RNAZ fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares ...
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics ...
Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 50% after announcing the acquisition of Polynoma and a $25 million strategic financing from a subsidiary of CK Life Sciences. The ...
BOSTON/SAN DIEGO - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a micro-cap biotech company currently valued at approximately $10 million, announced today it has acquired Polynoma LLC, a privately-held ...
First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded ...
No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results Several patients in the first and second cohort remain on ...
Transcode Therapeutics (NASDAQ: RNAZ) is up 1,969 % in premarket trading today. But the volume of shares traded is all of 727 according to NASDAQ itself. This is not normally how we think of stock ...
Transcode Therapeutics, Inc. (RNAZ) stock has tumbled to a 52-week low, reaching a price level of just $3.20. This significant downturn reflects a staggering 1-year change, with the company's stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results